Pfizer Disappoints Street

The street was disappointed with Pfizer's earnings and guidance. While there might have been a slight disappointment, the intrinsic value has changed very little in my eyes. A problem I had with owning Pfizer was that it was too widely loved and that should change now. If I could pick up the stock closer to $17, I will likely be a buyer. I currently have no position.

1 comment:

Anonymous said...

gsk